|
Market Closed -
Canadian Securities Exchange
19:34:03 05/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.0200 CAD | -.--% |
|
-.--% | -20.00% |
| Market Cap | 147K 126K 120K 108K 203K 14.01M 204K 1.42M 546K 7.13M 551K 538K 22.51M | P/E 2024 |
1.22x | P/E 2025 | -2.21x |
|---|---|---|---|---|---|
| Enterprise Value | 208K 179K 170K 154K 289K 19.88M 290K 2.02M 775K 10.11M 782K 764K 31.96M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
67.71% | Yield 2024 * |
-
| Yield 2025 | - |
Canadian Securities ExchangeCAD
| Markets | Quality | ||
|---|---|---|---|
Canadian Securities Exchange
| NSHS | Delayed | |
OTC Markets
| NSHSF | Delayed | |
|
Deutsche Boerse AG
| 2CG | Delayed | |
|
Börse Stuttgart
| 2CG | Delayed |
| Current year | -20.00% |
| Current year | 0.02 |  | 0.03 |
| 1 year | 0.02 | | 0.04 |
| 3 years | 0 | | 0.18 |
| 5 years | 0 | | 0.37 |
| 10 years | 0 | | 23.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Kaufman
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2013 |
Bennett Liu
DFI | Director of Finance/CFO | 33 | 01/11/2017 |
Toby Lim
CEO | Chief Executive Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Iverson
CHM | Chairman | 74 | 10/07/2019 |
Toby Lim
BRD | Director/Board Member | - | 17/11/2017 |
Richard Kaufman
BRD | Director/Board Member | - | 17/11/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 17/09/21 | Other | Director | 0 | 0% | ||
| 17/09/21 | Other | Director | 0 | 0% | ||
| 17/09/21 | Sell | Chairman | 338,956 | 6.2564% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | -20.00% | -.--% | 148K | |
| -1.13% | -3.11% | +13.82% | +60.66% | 46.21B | |
| -1.13% | -5.78% | +33.26% | +108.13% | 38.78B | |
| +0.12% | -0.08% | +7.12% | +78.27% | 11.68B | |
| -0.53% | -1.37% | -13.25% | +10.18% | 11.55B | |
| -0.38% | -2.26% | +18.18% | +139.63% | 9.14B | |
| +0.32% | -2.26% | +23.08% | +34.73% | 7.3B | |
| +0.17% | -0.74% | +13.44% | +197.13% | 7.15B | |
| -1.00% | -5.25% | +34.34% | -19.63% | 7.1B | |
| -3.13% | -4.30% | -44.88% | +11.66% | 4.97B | |
| Average | -0.67% | -2.33% | +6.51% | +62.08% | 14.39B | |
| Weighted average by Cap. | -0.86% | -3.27% | +16.06% | +75.66% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | 263K 227K 215K 195K 365K 25.16M 367K 2.55M 981K 12.8M 989K 967K 40.44M | -84.78K -73.05K -69.17K -62.69K -118K -8.1M -118K -821K -316K -4.12M -318K -311K -13.02M |
| Net Debt | 28.69K 24.72K 23.4K 21.21K 39.8K 2.74M 40K 278K 107K 1.39M 108K 105K 4.41M | 61.51K 53K 50.18K 45.49K 85.33K 5.88M 85.77K 596K 229K 2.99M 231K 226K 9.45M |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- NSHS Stock
Select your edition
All financial news and data tailored to specific country editions
